Long-term Management of CKD–Mineral and Bone Disorder
- 1 August 2012
- journal article
- case report
- Published by Elsevier BV in American Journal of Kidney Diseases
- Vol. 60 (2), 308-315
- https://doi.org/10.1053/j.ajkd.2012.01.027
Abstract
No abstract availableKeywords
This publication has 48 references indexed in Scilit:
- Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney diseaseKidney International, 2011
- Parathyroid hormone fragments inhibit active hormone and hypocalcemia-induced 1,25(OH)2D synthesisKidney International, 2007
- Fibroblast growth factor 23 impairs phosphorus and vitamin D metabolism in vivo and suppresses 25-hydroxyvitamin D-1α-hydroxylase expression in vitroAmerican Journal of Physiology-Renal Physiology, 2007
- Changes in Serum 25-Hydroxyvitamin D and Plasma Intact PTH Levels Following Treatment With Ergocalciferol in Patients With CKDAmerican Journal of Kidney Diseases, 2007
- Metabolic Bone Disease in Chronic Kidney DiseaseJournal of the American Society of Nephrology, 2007
- Chronic Kidney Disease–Mineral-Bone Disorder: A New ParadigmAdvances in Chronic Kidney Disease, 2007
- FGF-23 Is a Potent Regulator of Vitamin D Metabolism and Phosphate HomeostasisJournal of Bone and Mineral Research, 2004
- An Endocytic Pathway Essential for Renal Uptake and Activation of the Steroid 25-(OH) Vitamin D3Cell, 1999
- On the prevention of secondary hyperparathyroidism in experimental chronic renal disease using “proportional reduction” of dietary phosphorus intakeKidney International, 1972
- On the pathogenesis of hyperparathyroidism in chronic experimental renal insufficiency in the dogJCI Insight, 1971